Immunocore Holdings PLC
NASDAQ:IMCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
30
75.36
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Immunocore Holdings PLC
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | UK |
Market Cap | 1.6B USD |
Gross Margin |
99%
|
Country | FR |
Market Cap | 6T USD |
Gross Margin |
0%
|
Country | US |
Market Cap | 320.1B USD |
Gross Margin |
67%
|
Country | US |
Market Cap | 150.5B USD |
Gross Margin |
60%
|
Country | US |
Market Cap | 120.4B USD |
Gross Margin |
86%
|
Country | US |
Market Cap | 113.8B USD |
Gross Margin |
78%
|
Country | US |
Market Cap | 94.1B EUR |
Gross Margin |
76%
|
Country | AU |
Market Cap | 135.4B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 82.9B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 39.3B EUR |
Gross Margin |
75%
|
Country | NL |
Market Cap | 34.5B EUR |
Gross Margin |
89%
|
Immunocore Holdings PLC
Glance View
Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Immunocore Holdings PLC's most recent financial statements, the company has Gross Margin of 99.3%.